Skip to main content
Log in

Inflixmab as a possible treatment for the hemorrhagic type of Crohn’s disease

  • Case report
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Acute lower gastrointestinal bleeding is a rare complication of Crohn’s disease (CD). Although anti-tumor necrosis factor-Α (TNF-Α, infliximab) therapy has been established for patients with inflammatory and fistulous CD, there has been little evidence on whether infliximab is effective for the hemorrhagic type of CD. We report a case of a 31-year-old man with CD who had recurrent sudden-onset bloody stool. After a second surgery, he visited our hospital because of bloody stool. Infusion of infliximab stopped the bleeding and promoted the healing of ulcers in the ileum and ileocolon anastomosis. We suggest that infliximab therapy should be tried to stop acute gastrointestinal bleeding in CD before there is a surgical emergency.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsujikawa, T., Nezu, R., Andoh, A. et al. Inflixmab as a possible treatment for the hemorrhagic type of Crohn’s disease. J Gastroenterol 39, 284–287 (2004). https://doi.org/10.1007/s00535-003-1290-9

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-003-1290-9

Key words

Navigation